<DOC>
	<DOCNO>NCT02458313</DOCNO>
	<brief_summary>Obesity serious grow health problem United States . Obesity associate health problem type-2 diabetes cardiovascular disease , lead decrease quality life increase mortality . Given health quality-of-life effect obesity , develop effective treatment clearly important goal . This study plan learn effect investigational new drug ( DMXB-A ( 3- ( 2,4-dimethoxybenzylidene anabaseine ) ) effect obesity . The study drug similar effect nicotine . Since nicotine find affect appetite , investigator interest study effect study drug , similarity nicotine , brain responds thing picture food . The study drug approve Food Drug Administration ( FDA ) , consider experimental .</brief_summary>
	<brief_title>Nicotinic Agonist Effects BMI Neuronal Response</brief_title>
	<detailed_description />
	<mesh_term>Nicotinic Agonists</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>Overweight/obese ( BMI &gt; 27 ) Between 2165 year old Known cardiovascular disease ( e.g. , coronary artery disease , uncontrolled hypertension Women capable conception ( must postmenopausal , surgically sterilize , adhered anticontraception birth control regimen least 1 year ) Nicotine use Significant endocrine/metabolic disease Kidney disease Neurological illness Liver disease Medication use affect appetite and/or metabolism MRIspecific exclusion criterion ( e.g. , claustrophobia , metal body )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>